BMS-754807, another dual RTKI is being tested in a currently ongoing phase II trial (NCT01225172) in combination with letrozole in women with andvanced ER positive, non-steroidal aromatase inhibitor resistant breast tumors [132]. Here, ESR1 is linked to breast neoplasm.